Nexvet Biopharma PLC Company Profile (NASDAQ:NVET)

Analyst Ratings

Consensus Ratings for Nexvet Biopharma PLC (NASDAQ:NVET) (?)
Ratings Breakdown: 3 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $12.33 (135.30% upside)

Analysts' Ratings History for Nexvet Biopharma PLC (NASDAQ:NVET)
Show:
DateFirmActionRatingPrice TargetActions
5/14/2016Credit Suisse Group AGReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/24/2015Cowen and CompanyReiterated RatingBuy$13.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/24/2015Piper Jaffray Cos.Reiterated RatingOverweight$17.00 -> $13.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/3/2015JMP SecuritiesInitiated CoverageOutperform$17.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/2/2015Bank of America Corp.Initiated CoverageBuy$15.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/25/2014 forward)

Earnings

Earnings History for Nexvet Biopharma PLC (NASDAQ:NVET)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
5/12/2016        
5/12/2016Q3($0.44)($0.50)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/5/2015($0.51)($0.35)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/8/2015Q115($0.40)($0.36)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/16/2015($0.55)($2.01)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Nexvet Biopharma PLC (NASDAQ:NVET)
No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for Nexvet Biopharma PLC (NASDAQ:NVET)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Nexvet Biopharma PLC (NASDAQ:NVET)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
3/4/2016David GearingInsiderBuy11,113$3.33$37,006.29View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/2/2016Ashraf HannaDirectorBuy1,500$3.20$4,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/26/2016Farallon Capital Management LlInsiderBuy435,000$3.19$1,387,650.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/24/2016Cormac G KiltyDirectorBuy3,000$3.17$9,510.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/10/2015Farallon Capital Management LlInsiderBuy11,100$6.46$71,706.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/9/2015Cormac G KiltyDirectorBuy10,000$4.79$47,900.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/10/2015One Funds Management Ltd Atf AMajor ShareholderBuy100,000$10.00$1,000,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Nexvet Biopharma PLC (NASDAQ:NVET)
DateHeadline
07/25/16 09:59 AMIs $12 Price Target Attainable For Nexvet Biopharma plc (NASDAQ:NVET)? - Investor Newswire
07/22/16 08:30 AMNexvet Biopharma plc (NASDAQ:NVET): Sell-Side Ratings and Company Earnings Glance - Engelwood Daily
07/22/16 08:30 AMNexvet Biopharma Plc Ord (NASDAQ:NVET) Shorted Shares Increased 32.03% After Market Selling - Consumer Eagle
07/20/16 08:28 AMEquity Roundup: Stock Performance Focus on Nexvet Biopharma plc (NASDAQ:NVET) - Press Telegraph
07/20/16 04:30 AMNexvet Announces Publication of Two Peer-Reviewed Journal Articles Profiling Frunevetmab (NV-02) and Presentation at the Veterinary Pain Short Course Conference - [GlobeNewswire] - DUBLIN, Ireland, July 20, 2016-- Nexvet Biopharma, a veterinary biologic therapeutics company, today announced the recent publication of two peer-reviewed papers regarding frunevetmab in the Journal of ...
07/19/16 05:39 PMStrong Sell Calls For Nexvet Biopharma plc (NASDAQ:NVET) At 0 - Investor Newswire
07/15/16 10:27 AMNexvet Biopharma plc (NASDAQ:NVET) Earnings Concentration and Analyst Target Watch - Engelwood Daily
07/14/16 09:07 AMAnalyst Target and Average Rating Watch: Nexvet Biopharma plc (NASDAQ:NVET) - Press Telegraph
07/13/16 08:30 AMNexvet Biopharma plc (NASDAQ:NVET) Wall Street Analyst Recommendation Outlook - Telanagana Press
07/13/16 08:30 AMNexvet Biopharma Plc Ord (NASDAQ:NVET) Short Interest Decreased By 5.62% - Press Telegraph
07/10/16 04:55 PMIs $12 Within Reach For Nexvet Biopharma plc (NASDAQ:NVET)? - Investor Newswire
07/08/16 08:30 AMCompany Stock Focus for Nexvet Biopharma plc (NASDAQ:NVET): Which Way Will Shares Head? - Press Telegraph
07/08/16 08:30 AMNexvet Biopharma Plc Ord (NASDAQ:NVET) Sellers Covered 5.62% of Their Shorts - Press Telegraph
07/08/16 08:30 AMNexvet Biopharma Plc (NVET) Updated Price Targets - FTSE News
07/05/16 05:19 PMBroker Outlook For The Week Ahead Nexvet Biopharma Plc (NVET) - Fiscal Standard
07/03/16 09:48 AMBrokers Issue Average Price Target Of 13.00 On Nexvet Biopharma Plc (NVET) - Fiscal Standard
07/01/16 08:20 AMCovering the Bases on Nexvet Biopharma plc (NASDAQ:NVET): Where is the Stock Going? - Press Telegraph
07/01/16 08:20 AMNexvet Biopharma plc (NASDAQ:NVET) Earnings Glance and Target Price Review - Engelwood Daily
07/01/16 08:20 AMNew Broker Ratings For Nexvet Biopharma Plc (NVET) - FTSE News
06/27/16 05:27 PMNexvet Biopharma Plc Ord (NASDAQ:NVET) Sellers Covered 5.62% of Their Shorts - Engelwood Daily
06/26/16 04:45 PMStrong Sell Calls Recommendations For Nexvet Biopharma plc (NASDAQ:NVET) At 0 - Investor Newswire
06/26/16 04:45 PMCan Nexvet Biopharma plc (NASDAQ:NVET) Meet Analysts Expectations? - Stocks Daily
06/25/16 05:05 PMRecently Issued Stock Ratings For Nexvet Biopharma Plc (NVET) - Fiscal Standard
06/20/16 07:10 AMStrong Buy Calls Count For Nexvet Biopharma plc (NASDAQ:NVET) At 1 - Investor Newswire
06/20/16 07:10 AMThis Weeks Broker Views For Nexvet Biopharma Plc (NVET) - Fiscal Standard
06/13/16 08:30 AMTrend Of Rating Given To Nexvet Biopharma plc (NASDAQ:NVET) - Investor Newswire
06/10/16 04:02 PMNexvet Biopharma PLC :NVET-US: Earnings Analysis: Q3, 2016 By the Numbers : June 10, 2016 -
06/10/16 07:25 AMNexvet Biopharma (NVET) Jumps: Stock Moves 9.2% Higher -
06/03/16 06:01 PMStock Review and Earnings Check on Nexvet Biopharma plc (NASDAQ:NVET) - HNN
06/02/16 08:32 AMNexvet Biopharma Plc (NVET) Do Brokers Advise Buy, Sell Or Hold? - Share Trading News - Nexvet Biopharma Plc (NVET) Do Brokers Advise Buy, Sell Or Hold?Share Trading NewsMarket analysts have recently updated their ratings and price targets on shares of Nexvet Biopharma plc (NVET). The latest reports which are currently in issue on Thursday 2nd of June state 0 analysts have a rating of “strong buy”, 0 analysts “buy”, 0 ...and more »
06/01/16 06:03 PMTarget Price and Stock Performance Rundown for Nexvet Biopharma plc (NASDAQ:NVET) - HNN - Target Price and Stock Performance Rundown for Nexvet Biopharma plc (NASDAQ:NVET)HNNKeeping an eye on share activity using multiple views may be helpful when tracking stock performance. Equity investors have the ability to track short or long term share performance. During the latest trading session, Nexvet Biopharma plc (NASDAQ:NVET) ...and more »
05/30/16 08:58 PMNexvet Biopharma Plc (NVET) Broker Price Targets For The Coming Week - Share Trading News - Nexvet Biopharma Plc (NVET) Broker Price Targets For The Coming WeekShare Trading NewsMarket analysts have recently updated their ratings and price targets on shares of Nexvet Biopharma plc (NVET). The latest reports which are currently in issue on Monday 30th of May state 0 analysts have a rating of “strong buy”, 0 analysts “buy”, 0 ...Nexvet Biopharma Plc Ord (NASDAQ:NVET) Short Interest Increased By 0.71%The Postall 4 news articles »
05/28/16 12:19 PMEarnings Review and Stock Rundown for Nexvet Biopharma plc (NASDAQ:NVET) - Wall Street Hints and News - Earnings Review and Stock Rundown for Nexvet Biopharma plc (NASDAQ:NVET)Wall Street Hints and NewsInvestors and analysts will be paying close attention when the company posts earnings results. Earnings numbers can provide insight into a company's overall profitability. Covering equity analysts are expecting Nexvet Biopharma plc (NASDAQ:NVET) to ...
05/27/16 04:37 AMNexvet Provides Update on Upcoming Investor Symposium at Irish Biomanufacturing Facility - [at noodls] - DUBLIN, Ireland, May 27, 2016 (GLOBE NEWSWIRE) -- Nexvet Biopharma (Nasdaq:NVET), a veterinary biologic therapeutics company, is pleased to provide an update on its Investor Symposium, which will be held ...
05/26/16 12:24 PMLatest Analyst Ratings For Nexvet Biopharma Plc (NVET) - Share Trading News - Latest Analyst Ratings For Nexvet Biopharma Plc (NVET)Share Trading NewsNexvet Biopharma plc has a 50 day moving average of 3.02 and a 200 day moving average of 3.35. The stock's market capitalization is 33.07M, it has a 52-week low of 2.61 and a 52-week high of 11.30. The share price of the company (NVET) was up +1.42% ...
05/26/16 12:24 PMNexvet Biopharma (NVET) Flat on Study Results - Nexvet Biopharma plc (NASDAQ: NVET) shares rose 0.1% to $2.93 as the company reported positive results from NV-02 pilot field study in cats with osteoarthritis. Share volume was 102,000 compared to an all-day average of 11,000
05/26/16 09:19 AMNexvet Biopharma Gains 15%, Company Reports Positive Results From Pilot Field Study - Shares of Nexvet Biopharma plc (NASDAQ: NVET), a nano-cap clinical-stage biopharmaceutical company that focuses on developing therapies for companion animals, surged higher by more than 15 percent early Thursday morning. Nexvet Biopharma reported results from its NV-02 pilot field study in cats with osteoarthritis. The company said that the study achieved statistically significant efficacy results in the study and plans on proceeded to a pivotal (human ...Full story available on Benzinga.com
05/26/16 04:57 AMNexvet Announces Positive Results from NV-02 Pilot Field Study in Cats with Osteoarthritis - [at noodls] - DUBLIN, Ireland, May 26, 2016 (GLOBE NEWSWIRE) -- Nexvet Biopharma (Nasdaq:NVET), a veterinary biologic therapeutics company, today announced statistically significant efficacy results from its randomized, ...
05/26/16 04:37 AM5:37 am Nexvet Biopharma reports positive results from NV-02 Pilot Field Study; NV-02 Pivotal Study plans underway -
05/12/16 06:07 AMQ3 2016 Nexvet Biopharma plc Earnings Release - Time Not Supplied -
05/12/16 04:47 AMNexvet Reports Financial Results for Third Quarter of Fiscal Year 2016 - [at noodls] - DUBLIN, Ireland, May 12, 2016 (GLOBE NEWSWIRE) -- Nexvet Biopharma (Nasdaq:NVET), a veterinary biologics developer, today announced its financial results for the three and nine-month periods ended March ...
05/11/16 05:42 AMNexvet to Host Symposium at American College of Veterinary Internal Medicine (ACVIM) Forum to Present Additional NV-01 Pivotal Data in Canine Pain and Clinical Data for NV-02 in Feline Pain - [at noodls] - DUBLIN, Ireland, May 11, 2016 (GLOBE NEWSWIRE) -- Nexvet Biopharma (Nasdaq:NVET), a veterinary biologics developer, today announced it will host a symposium to present expanded pivotal safety and efficacy ...
05/04/16 05:00 AMNexvet to Host Investor Symposium at its Irish Biomanufacturing Facility - [at noodls] - DUBLIN, Ireland, May 04, 2016 (GLOBE NEWSWIRE) -- Nexvet Biopharma (Nasdaq:NVET), a veterinary biologics developer, today announced the hosting of an Investor Symposium on June 3, 2016 at BioNua, its veterinary ...
05/02/16 04:40 AMNexvet and Zenoaq Announce PD-1 mAb Candidate for Canine Cancer - [at noodls] - DUBLIN, Ireland, May 02, 2016 (GLOBE NEWSWIRE) -- Nexvet Biopharma (Nasdaq:NVET), a veterinary biologics developer, and Zenoaq (Nippon Zenyaku Kogyo Co., Ltd.), a leading Japanese animal health company, ...
02/26/16 01:42 PMNexvet Biopharma Plc (NVET) Updated Price Targets - Share Trading News - Nexvet Biopharma Plc (NVET) Updated Price TargetsShare Trading NewsRecently analysts working for a variety of stock market brokerages have changed their consensus ratings and price targets on shares of Nexvet Biopharma plc (NVET). The most recent broker reports which have been released note that 0 analysts have a ...Nexvet Biopharma Plc Ord (NASDAQ:NVET) Sellers Increased By 20.47% Their ShortsSmallCapWired.comNexvet Biopharma plc Stock Is Rising NowBusiness Standard Tribuneall 3 news articles »
11/24/15 04:39 AMNexvet to Present at the 27th Annual Piper Jaffray Healthcare Conference - [at noodls] - DUBLIN, Ireland, Nov. 24, 2015 (GLOBE NEWSWIRE) -- Nexvet Biopharma (Nasdaq:NVET), a veterinary biologics developer, today announced that Dr. Mark Heffernan, Nexvet's Chief Executive Officer, is scheduled ...
11/23/15 08:08 AMNEXVET BIOPHARMA PLC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits -
11/23/15 05:21 AMNexvet Biopharma plc (Nasdaq: NVET) to Ring The Nasdaq Stock Market Closing Bell - [at noodls] - ADVISORY, Nov. 23, 2015 (GLOBE NEWSWIRE) -- What: Nexvet Biopharma plc (Nasdaq:NVET), a global, clinical-stage, veterinary biologics developer, will visit the Nasdaq MarketSite in Times Square to celebrate ...
11/20/15 03:31 PMNEXVET BIOPHARMA PLC Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Submission -
11/16/15 05:04 AMNexvet Announces Positive Results From NV-01 Pivotal Study in Dogs With Osteoarthritis - [at noodls] - Primary Endpoint Achieved Conference Call November 16th at 9:00AM ET DUBLIN, Ireland, Nov. 16, 2015 (GLOBE NEWSWIRE) -- Nexvet Biopharma (Nasdaq:NVET), a veterinary biologics developer, today announced ...

Social

About Nexvet Biopharma PLC

Nexvet Biopharma PLC logoNexvet Biopharma public limited company is a clinical-stage biopharmaceutical company focusing on developing therapies for companion animals. The Company is engaged in developing and commercializing species-specific biologics based on human biologics. The Company's PETization platform is an algorithmic approach that enables it to create monoclonal antibodies that are designed as self or native by an animal's immune system. The Company uses PETization to convert human and rodent monoclonal antibodies (mAbs) into species-specific canine, feline and equine mAbs. The Company's products include NV-01, NV-02 and NV-08. NV-01 is a mAb for the control of pain associated with osteoarthritis in dogs. NV-02 is a mAb for the control of pain associated with degenerative joint disease in cats. NV-08 is a receptor fusion protein for the treatment of chronic inflammatory diseases, including atopic dermatitis, in dogs.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: NVET
  • CUSIP:
Key Metrics:
  • Previous Close: $5.31
  • 50 Day Moving Average: $4.68
  • 200 Day Moving Average: $3.55
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $62.32M
  • Beta: 0.22
  • Current Year EPS Consensus Estimate: $-1.8200 EPS
  • Next Year EPS Consensus Estimate: $-1.9600 EPS
Additional Links:
Nexvet Biopharma PLC (NASDAQ:NVET) Chart for Monday, July, 25, 2016